{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:10:22Z","timestamp":1790741422983,"version":"4.1.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The rapid global increase in multidrug-resistant (MDR) bacteria has compromised the effectiveness of conventional antibiotics, stressing the urgent need for alternative antimicrobial strategies. CRISPR\u2013Cas systems, originally evolved as bacterial adaptive immune mechanisms, provide programmable and highly specific tools for targeting antimicrobial resistance (AMR) determinants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review aims to evaluate the antibacterial mechanisms, delivery strategies, preclinical evidence, safety considerations, and translational potential of CRISPR\u2013Cas systems for combating MDR bacterial infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic literature search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science up to January 2026 in accordance with PRISMA 2020 guidelines. Eligible studies included original\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      experimental or preclinical investigations assessing CRISPR\u2013Cas systems (Cas9, Cas12, Cas13, or related effectors) for antibacterial activity or antibiotic resensitization. Data were extracted on CRISPR effector type, bacterial target, delivery platform, and therapeutic outcome. Due to methodological heterogeneity, results were synthesized narratively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most studies reported effective killing or resensitization of MDR bacteria through chromosomal double-strand break induction, resistance plasmid curing, integron disruption, or RNA-targeted cleavage. Cas9 was the most frequently employed effector, followed by Cas12 and Cas13. Delivery strategies included bacteriophages, conjugative plasmids, and nanoparticle-based systems, with phage-mediated delivery demonstrating the most consistent efficacy in complex environments and animal models. Notably, a CRISPR-enhanced engineered bacteriophage cocktail (LBP-EC01) has advanced to clinical evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, the evidence supports CRISPR\u2013Cas antimicrobials as a promising precision-based approach for addressing AMR. However, major barriers remain, including limited host range, instability in physiological environments, emergence of escape mutations, and insufficient data on off-target effects and long-term safety. Addressing these challenges through optimized delivery platforms, multiplex targeting strategies, and standardized safety and regulatory frameworks will be essential for clinical translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261319789<\/jats:ext-link>\n                      , identifier CRD4201319789.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1747931","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:36Z","timestamp":1778473416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Maha S. I.","family":"Wizrah","sequence":"first","affiliation":[{"name":"Department of Biology, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University","place":["Al-Kharj, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"aaf5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector.","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.2147\/IDR.S494327","article-title":"CRISPR-Cas systems in the fight against antimicrobial resistance: current status, potentials, and future directions.","volume":"17","author":"Ahmed","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3390\/pharmaceutics14112533","article-title":"Instability challenges and stabilization strategies of pharmaceutical proteins.","volume":"14","author":"Akbarian","year":"2022","journal-title":"Pharmaceutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10185","DOI":"10.2147\/IJN.S479068","article-title":"Current Updates of CRISPR\/Cas System and Anti-CRISPR Proteins: innovative applications to improve the genome editing strategies.","volume":"19","author":"Allemailem","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"B5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1089\/crispr.2021.0148","article-title":"Regulatory considerations for clinical trial applications with CRISPR-based medicinal products.","volume":"5","author":"Anliker","year":"2022","journal-title":"CRISPR J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/BTT.S429411","article-title":"Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing.","volume":"18","author":"Asmamaw Mengstie","year":"2024","journal-title":"Biologics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e01486-21","DOI":"10.1128\/AEM.01486-21.","article-title":"Cross-Genus \u201cBoot-Up\u201d of synthetic bacteriophage in staphylococcus aureus by using a new and efficient DNA transformation method.","volume":"88","author":"Assad-Garcia","year":"2022","journal-title":"Appl. Environ. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.31.573511","article-title":"Precision genome editing unveils a breakthrough in reversing antibiotic resistance: CRISPR\/Cas9 targeting of multi-drug resistance genes in methicillin-resistant Staphylococcus aureus.","author":"Ates","year":"2024","journal-title":"bioRxiv [Preprint]."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s44149-023-00065-z","article-title":"CRISPR-Cas9 mediated phage therapy as an alternative to antibiotics.","volume":"3","author":"Balcha","year":"2023","journal-title":"Anim. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101462","DOI":"10.1016\/j.imu.2024.101462","article-title":"Development and design of CRISPR-based diagnostic for Acinetobacter baumannii by employing off-target gene editing of sgRNA.","volume":"46","author":"Baqar","year":"2024","journal-title":"Informat. Med. Unlocked"},{"key":"B11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.molcel.2014.03.011","article-title":"CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity.","volume":"54","author":"Barrangou","year":"2014","journal-title":"Mol. Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"124054","DOI":"10.1016\/j.ijbiomac.2023.124054","article-title":"CRISPR-Cas for genome editing: classification, mechanism, designing and applications.","volume":"238","author":"Bhatia","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mib.2017.08.005","article-title":"Using CRISPR-Cas systems as antimicrobials.","volume":"37","author":"Bikard","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"gkaf752","DOI":"10.1093\/nar\/gkaf752","article-title":"A versatile anti-CRISPR platform for opto- and chemogenetic control of CRISPR-Cas9 and Cas12 across a wide range of orthologs.","volume":"53","author":"Brenker","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.ijmmb.2024.100771","article-title":"CRISPR-Cas-assisted phage engineering for personalized antibacterial treatments.","volume":"53","author":"Chaudhary","year":"2025","journal-title":"Indian J. Med. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs CRISPR\u2013Cas9 targeting accuracy.","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","article-title":"Recent progress in targeted delivery vectors based on biomimetic nanoparticles.","volume":"6","author":"Chen","year":"2021","journal-title":"Sig. Transduct. Target Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/antibiotics13121141","article-title":"Current knowledge on CRISPR strategies against antimicrobial-resistant bacteria.","volume":"13","author":"De La Fuente, Tagarro","year":"2024","journal-title":"Antibiotics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2018.09.017","article-title":"Exploiting a conjugative CRISPR\/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli.","volume":"53","author":"Dong","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100854","DOI":"10.1016\/j.ajps.2023.100854","article-title":"CRISPR\/Cas9 systems: delivery technologies and biomedical applications.","volume":"18","author":"Du","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"dmm032151","DOI":"10.1242\/dmm.032151","article-title":"Use of zebrafish to study Shigella infection.","volume":"11","author":"Duggan","year":"2018","journal-title":"Dis. Models Mech."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1039\/d2ma00980c","article-title":"Advancements in bacteriophage therapies and delivery for bacterial infection.","volume":"4","author":"Durr","year":"2023","journal-title":"Mater. Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2000315","DOI":"10.1002\/bies.202000315","article-title":"CRISPR\/Cas technology as a promising weapon to combat viral infections.","volume":"43","author":"Escalona-Noguero","year":"2021","journal-title":"BioEssays"},{"key":"B24","doi-asserted-by":"publisher","first-page":"167952","DOI":"10.1016\/j.jmb.2023.167952","article-title":"Anti-CRISPR discovery: using magnets to find needles in haystacks.","volume":"435","author":"Forsberg","year":"2023","journal-title":"J. Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"107295","DOI":"10.1016\/j.jbc.2024.107295","article-title":"Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.","volume":"300","author":"Ganguly","year":"2024","journal-title":"J. Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11033-025-10332-6","article-title":"Engineering bacteriophages for targeted superbug eradication.","volume":"52","author":"Ghaznavi","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/15476286.2018.1504546","article-title":"PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures.","volume":"16","author":"Gleditzsch","year":"2019","journal-title":"RNA Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tim.2019.08.005","article-title":"The case for modeling human infection in Zebrafish.","volume":"28","author":"Gomes","year":"2020","journal-title":"Trends Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"866800","DOI":"10.3389\/fcell.2022.866800","article-title":"Cas13d: a new molecular scissor for transcriptome engineering.","volume":"10","author":"Gupta","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"21136","DOI":"10.1039\/d0ra03580g","article-title":"Cytotoxic effect of green silver nanoparticles against ampicillin-resistant Klebsiella pneumoniae.","volume":"10","author":"Hamida","year":"2020","journal-title":"RSC Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/antibiotics14090865","article-title":"Biofilms exposed: innovative imaging and therapeutic platforms for persistent infections.","volume":"14","author":"Haval","year":"2025","journal-title":"Antibiotics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering.","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20150496","DOI":"10.1098\/rstb.2015.0496","article-title":"CRISPR-Cas: biology, mechanisms and relevance.","volume":"371","author":"Hille","year":"2016","journal-title":"Phil. Trans. R. Soc. B"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering.","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1021\/acssynbio.2c00465","article-title":"P1 Bacteriophage-Enabled Delivery of CRISPR-Cas9 antimicrobial activity against Shigella flexneri.","volume":"12","author":"Huan","year":"2023","journal-title":"ACS Synth. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms21249604","article-title":"Various aspects of a gene editing system\u2014CRISPR\u2013Cas9.","volume":"21","author":"Janik","year":"2020","journal-title":"IJMS"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/antibiotics12061075","article-title":"CRISPR-Cas9 system: a prospective pathway toward combatting antibiotic resistance.","volume":"12","author":"Javed","year":"2023","journal-title":"Antibiotics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12951-024-03065-4","article-title":"Gene editing tool-loaded biomimetic cationic vesicles with highly efficient bacterial internalization for in vivo eradication of pathogens.","volume":"22","author":"Jia","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1080\/10717544.2017.1410259","article-title":"Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles.","volume":"24","author":"Ju","year":"2017","journal-title":"Drug Delivery"},{"key":"B40","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/ph16070920","article-title":"CRISPR-based gene editing in Acinetobacter baumannii to combat antimicrobial resistance.","volume":"16","author":"Junaid","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e34692","DOI":"10.1016\/j.heliyon.2024.e34692","article-title":"Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.","volume":"10","author":"Kadkhoda","year":"2024","journal-title":"Heliyon"},{"key":"B42","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1021\/acs.bioconjchem.6b00676","article-title":"Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance.","volume":"28","author":"Kang","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"102304","DOI":"10.1016\/j.rechem.2025.102304","article-title":"Innovative strategies in the fight against bacterial infections: Phage therapy, nanotechnology, and new antimicrobial agents for multidrug-resistant pathogens.","volume":"15","author":"Kashyap","year":"2025","journal-title":"Results Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components.","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharmaceut."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41467-020-16731-6","article-title":"Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria.","volume":"11","author":"Kiga","year":"2020","journal-title":"Nat. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","article-title":"Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.","volume":"24","author":"Kim","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.05.602127","article-title":"Effectiveness of CRISPR-Cas in sensitizing bacterial populations with plasmid-encoded antimicrobial resistance.","author":"Kippnich","year":"2024","journal-title":"bioRxiv [Preprint]."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0044-1785234","article-title":"CRISPR\u2013Cas9 gene editing: curing genetic diseases by inherited epigenetic modifications.","volume":"11","author":"Kolanu","year":"2024","journal-title":"Global Med. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1093\/gbe\/evx192","article-title":"Mobile genetic elements and evolution of CRISPR-Cas systems: all the way there and back.","volume":"9","author":"Koonin","year":"2017","journal-title":"Genome Biol. Evol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1021\/acs.biochem.3c00159","article-title":"Discovery of diverse CRISPR-Cas systems and expansion of the genome engineering toolbox.","volume":"62","author":"Koonin","year":"2023","journal-title":"Biochemistry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments.","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.copbio.2020.11.003","article-title":"Enhancing phage therapy through synthetic biology and genome engineering.","volume":"68","author":"Lenneman","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1260883","DOI":"10.3389\/fmolb.2023.1260883","article-title":"Advances in the application of CRISPR-Cas technology in rapid detection of pathogen nucleic acid.","volume":"10","author":"Li","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.chom.2020.12.007","article-title":"Anti-CRISPRs go viral: the infection biology of CRISPR-Cas inhibitors.","volume":"29","author":"Li","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B55","doi-asserted-by":"publisher","first-page":"14473","DOI":"10.1074\/jbc.REV120.007034","article-title":"Chemistry of Class 1 CRISPR-Cas effectors: binding, editing, and regulation.","volume":"295","author":"Liu","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-021-00480-z","article-title":"Engineered bacteriophage therapeutics: rationale, challenges and future.","volume":"35","author":"\u0141obocka","year":"2021","journal-title":"BioDrugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial antibiotic resistance: the most critical pathogens.","volume":"10","author":"Mancuso","year":"2021","journal-title":"Pathogens"},{"key":"B58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/epidemiologia6020021","article-title":"The global burden of multidrug-resistant bacteria.","volume":"6","author":"Marino","year":"2025","journal-title":"Epidemiologia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41592-020-0771-6","article-title":"Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies.","volume":"17","author":"Marino","year":"2020","journal-title":"Nat. Methods"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1021\/acsinfecdis.2c00649","article-title":"CRISPR-Cas-Based antimicrobials: design, challenges, and bacterial mechanisms of resistance.","volume":"9","author":"Mayorga-Ramos","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41467-020-15053-x","article-title":"Multiplexed CRISPR technologies for gene editing and transcriptional regulation.","volume":"11","author":"McCarty","year":"2020","journal-title":"Nat. Commun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"111274","DOI":"10.1016\/j.forsciint.2022.111274","article-title":"CRISPR\/Cas9: regulations and challenges for law enforcement to combat its dual-use.","volume":"334","author":"Mir","year":"2022","journal-title":"Forensic Sci. Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"112743","DOI":"10.1016\/j.biopha.2022.112743","article-title":"Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections.","volume":"148","author":"Najafi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"113122","DOI":"10.1016\/j.biopha.2022.113122","article-title":"Phage delivered CRISPR-Cas system to combat multidrug-resistant pathogens in gut microbiome.","volume":"151","author":"Nath","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1511149","DOI":"10.3389\/fbioe.2024.1511149","article-title":"Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine.","volume":"12","author":"Nazir","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12934-025-02661-9","article-title":"Cell-free expression system: a promising platform for bacteriophage production and engineering.","volume":"24","author":"Nour El-Din","year":"2025","journal-title":"Microb Cell Fact."},{"key":"B67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jmb.2018.06.029","article-title":"Molecular mechanisms of RNA targeting by Cas13-containing Type VI CRISPR\u2013Cas Systems.","volume":"431","author":"O\u2019Connell","year":"2019","journal-title":"J. Mol. Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41182-025-00728-2","article-title":"Reinvigorating AMR resilience: leveraging CRISPR\u2013Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security\u2014a systematic review.","volume":"53","author":"Okesanya","year":"2025","journal-title":"Trop. Med. Health"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.53771\/ijlsra.2025.9.1.0042","article-title":"Phage-based CRISPR delivery systems for targeted eradication of drug-resistant bacterial infections.","volume":"9","author":"Onyeyili","year":"2025","journal-title":"Int. J. Life Sci. Res. Arch."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/v12111223","article-title":"Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 infection with inhibition of viral escape.","volume":"12","author":"Ophinni","year":"2020","journal-title":"Viruses"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies.","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"lsad030","DOI":"10.1093\/jlb\/lsad030","article-title":"CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations.","volume":"11","author":"Pacia","year":"2024","journal-title":"J. Law Biosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1009672","DOI":"10.1371\/journal.ppat.1009672","article-title":"CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria.","volume":"17","author":"Palacios Araya","year":"2021","journal-title":"PLoS Pathog."},{"key":"B74","doi-asserted-by":"publisher","first-page":"102634","DOI":"10.1016\/j.omtn.2025.102634","article-title":"Recent applications, future perspectives, and limitations of the CRISPR-Cas system.","volume":"36","author":"Park","year":"2025","journal-title":"Mol. Therapy Nucleic Acids"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.cell.2016.11.017","article-title":"Naturally occurring off-switches for CRISPR-Cas9.","volume":"167","author":"Pawluk","year":"2016","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR\u2013Cas technologies and applications.","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/s41467-024-47416-z","article-title":"Diverse and abundant phages exploit conjugative plasmids.","volume":"15","author":"Quinones-Olvera","year":"2024","journal-title":"Nat. Commun."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1483279","DOI":"10.3389\/fbioe.2024.1483279","article-title":"Navigating biosafety regulatory frameworks for genetic engineering in Africa: a focus on genome editing and gene drive technologies.","volume":"12","author":"Rabuma","year":"2024","journal-title":"Front. Bioeng. Biotechnol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1284547","DOI":"10.3389\/fgeed.2023.1284547","article-title":"What do people think about genetic engineering? A systematic review of questionnaire surveys before and after the introduction of CRISPR.","volume":"5","author":"Ramos","year":"2023","journal-title":"Front. Genome Ed."},{"key":"B80","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cell.2016.12.009.","article-title":"Inhibition of CRISPR-Cas9 with bacteriophage proteins.","volume":"168","author":"Rauch","year":"2017","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"903812","DOI":"10.3389\/fcell.2022.903812","article-title":"Cas-Based Systems for RNA editing in gene therapy of monogenic diseases: in vitro and in vivo application and translational potential.","volume":"10","author":"Reshetnikov","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B82","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1039\/c3cs35504g","article-title":"Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors","volume":"42","author":"Reymond","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e01454-19","DOI":"10.1128\/AAC.01454-19","article-title":"Conjugative delivery of CRISPR-Cas9 for the selective depletion of antibiotic-resistant Enterococci.","volume":"63","author":"Rodrigues","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"100344","DOI":"10.1016\/j.microb.2025.100344","article-title":"CRISPR Cas systems: from bacterial defense mechanisms to revolutionary tools reshaping genetic research and translation therapeutics.","volume":"7","author":"Saeed","year":"2025","journal-title":"Microbe"},{"key":"B85","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12916-025-04323-4","article-title":"Innovative approaches to combat antibiotic resistance: integrating CRISPR\/Cas9 and nanoparticles against biofilm-driven infections.","volume":"23","author":"Saffari Natanzi","year":"2025","journal-title":"BMC Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/antibiotics14010085","article-title":"The evolution of antimicrobial resistance in Acinetobacter baumannii and new strategies to fight it.","volume":"14","author":"Scoffone","year":"2025","journal-title":"Antibiotics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","article-title":"CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases.","volume":"29","author":"Sharma","year":"2021","journal-title":"Mol. Therapy"},{"key":"B88","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/pathogens11030292","article-title":"Recent strategies to combat biofilms using antimicrobial agents and therapeutic approaches.","volume":"11","author":"Shrestha","year":"2022","journal-title":"Pathogens"},{"key":"B89","doi-asserted-by":"publisher","first-page":"27128","DOI":"10.1038\/srep27128","article-title":"Structural studies of a lipid-binding peptide from tunicate hemocytes with anti-biofilm activity.","volume":"6","author":"Silva","year":"2016","journal-title":"Sci. Rep."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.28.645910","article-title":"Exploring Clinical Class 1 integrons as valuable targets for the re-sensitization of multidrug resistant pathogenic bacteria using CRISPR-Cas.","author":"Skovmand","year":"2025","journal-title":"bioRxiv [Preprint]."},{"key":"B91","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","article-title":"Phage therapy: from biological mechanisms to future directions.","volume":"186","author":"Strathdee","year":"2023","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fmicb.2020.00578","article-title":"Exploring the potential of CRISPR-Cas9 under challenging conditions: facing high-copy plasmids and counteracting beta-lactam resistance in clinical strains of Enterobacteriaceae.","volume":"11","author":"Tagliaferri","year":"2020","journal-title":"Front. Microbiol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.2147\/IDR.S370869","article-title":"The application of the CRISPR-Cas system in antibiotic resistance.","volume":"15","author":"Tao","year":"2022","journal-title":"IDR"},{"key":"B94","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12866-023-03058-7","article-title":"Elimination of blaKPC-2-mediated carbapenem resistance in Escherichia coli by CRISPR-Cas9 system.","volume":"23","author":"Tao","year":"2023","journal-title":"BMC Microbiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e0329638","DOI":"10.1371\/journal.pone.0329638","article-title":"CRISPR\/Cas9-targeted smpB mutation revealing roles in biofilm formation, motility, and antibiotic susceptibility in Acinetobacter baumannii.","volume":"20","author":"Thavorasak","year":"2025","journal-title":"PLoS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1021\/acssynbio.0c00467","article-title":"Engineering bacteria to produce pure phage-like particles for gene delivery.","volume":"10","author":"Tridgett","year":"2021","journal-title":"ACS Synth. Biol."},{"key":"B97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-12-817870-6.00011-0","article-title":"Upscaling and GMP production of pharmaceutical drug delivery systems","volume-title":"Drug Delivery Trends","author":"T\u00fcreli","year":"2020"},{"key":"B98","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/pathogens10020205","article-title":"Genomic and phenotypic analysis of multidrug-resistant Acinetobacter baumannii clinical isolates carrying different types of CRISPR\/Cas Systems.","volume":"10","author":"Tyumentseva","year":"2021","journal-title":"Pathogens"},{"key":"B99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41579-022-00793-y","article-title":"RNA-targeting CRISPR\u2013Cas systems.","volume":"21","author":"Van Beljouw","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.gmg.2025.100042","article-title":"Exploring molecular mechanisms of drug resistance in bacteria and progressions in CRISPR\/Cas9-based genome expurgation solutions.","volume":"12","author":"Vivekanandan","year":"2025","journal-title":"Glob. Med. Genet."},{"key":"B101","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12951-024-02576-4","article-title":"Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e34383","DOI":"10.1016\/j.heliyon.2024.e34383","article-title":"The application of CRISPR-Cas system in Staphylococcus aureus infection.","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B103","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s11658-023-00483-4","article-title":"CRISPR applications in cancer diagnosis and treatment.","volume":"28","author":"Wang","year":"2023","journal-title":"Cell Mol. Biol. Lett."},{"key":"B104","doi-asserted-by":"publisher","first-page":"112430","DOI":"10.1016\/j.bios.2020.112430","article-title":"CRISPR\/cas systems redefine nucleic acid detection: Principles and methods.","volume":"165","author":"Wang","year":"2020","journal-title":"Biosens. Bioelectron."},{"key":"B105","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13238-021-00824-z","article-title":"Indiscriminate ssDNA cleavage activity of CRISPR-Cas12a induces no detectable off-target effects in mouse embryos.","volume":"12","author":"Wei","year":"2021","journal-title":"Protein Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1353\/pbm.2020.0006","article-title":"CRISPR cautions: biosecurity implications of gene editing.","volume":"63","author":"West","year":"2020","journal-title":"Perspect. Biol. Medi."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-024-03962-0","article-title":"Advances in miniature CRISPR-Cas proteins and their applications in gene editing.","volume":"206","author":"Wu","year":"2024","journal-title":"Arch Microbiol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12951-021-01132-8","article-title":"Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections.","volume":"19","author":"Wu","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1002\/mco2.327","article-title":"Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models.","volume":"4","author":"Xuan","year":"2023","journal-title":"MedComm"},{"key":"B110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/bfgp\/elac037","article-title":"Role of gut-microbiota in disease severity and clinical outcomes.","volume":"23","author":"Yadav","year":"2024","journal-title":"Brief. Funct. Genomics"},{"key":"B111","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10565-019-09489-1","article-title":"CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.","volume":"35","author":"Yan","year":"2019","journal-title":"Cell Biol. Toxicol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41589-024-01593-6","article-title":"Structures, mechanisms and applications of RNA-centric CRISPR\u2013Cas13.","volume":"20","author":"Yang","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"106475","DOI":"10.1016\/j.ijantimicag.2021.106475","article-title":"Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.","volume":"59","author":"Yeh","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e03884-23","DOI":"10.1128\/spectrum.03884-23","article-title":"Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR\/Cas9 system.","volume":"12","author":"Zhang","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B115","doi-asserted-by":"publisher","first-page":"108382","DOI":"10.1016\/j.biotechadv.2024.108382","article-title":"The type V effectors for CRISPR\/Cas-mediated genome engineering in plants.","volume":"74","author":"Zhang","year":"2024","journal-title":"Biotechnol. Adv."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/microorganisms11102454","article-title":"Gut Phageome\u2014an insight into the role and impact of gut microbiome and their correlation with mammal health and diseases.","volume":"11","author":"Zhang","year":"2023","journal-title":"Microorganisms"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1137947","DOI":"10.3389\/fcimb.2023.1137947","article-title":"Understanding bacterial biofilms: from definition to treatment strategies.","volume":"13","author":"Zhao","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/bios15100660","article-title":"CRISPR-Cas-based diagnostics in biomedicine: principles, applications, and future trajectories.","volume":"15","author":"Zhou","year":"2025","journal-title":"Biosensors"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1747931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:37Z","timestamp":1778473417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1747931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":118,"alternative-id":["10.3389\/fmicb.2026.1747931"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1747931","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1747931"}}